PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.68%
Negative revenue growth while AVGO stands at 0.59%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
9.32%
Gross profit growth above 1.5x AVGO's 0.51%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
43.39%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
33.50%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
15.24%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
20.00%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
20.00%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
45.37%
Share count expansion well above AVGO's 0.26%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
42.90%
Slight or no buyback while AVGO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-33.23%
Dividend reduction while AVGO stands at 0.14%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-24.69%
Negative OCF growth while AVGO is at 7.23%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-19.83%
Negative FCF growth while AVGO is at 6.62%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-33.03%
Negative 10Y revenue/share CAGR while AVGO stands at 409.54%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-57.43%
Negative 5Y CAGR while AVGO stands at 122.61%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-63.08%
Negative 3Y CAGR while AVGO stands at 60.90%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
-37.86%
Negative 5Y OCF/share CAGR while AVGO is at 73.80%. Joel Greenblatt would question the firm’s operational model or cost structure.
-46.80%
Negative 3Y OCF/share CAGR while AVGO stands at 34.25%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
12.76%
Below 50% of AVGO's 691.11%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-27.94%
Negative 5Y net income/share CAGR while AVGO is 651.30%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-56.65%
Negative 3Y CAGR while AVGO is 66.58%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
115.41%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
42.97%
Below 50% of AVGO's 147.32%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
6.40%
Below 50% of AVGO's 188.08%. Michael Burry suspects a serious short-term disadvantage in building book value.
29.25%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
-1.57%
Negative 5Y dividend/share CAGR while AVGO stands at 71.80%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-33.25%
Negative near-term dividend growth while AVGO invests at 38.29%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-2.35%
Firm’s AR is declining while AVGO shows 14.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
8.42%
Inventory growth well above AVGO's 5.71%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
6.96%
Positive asset growth while AVGO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-25.51%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-1.07%
We’re deleveraging while AVGO stands at 1.06%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-3.44%
Our R&D shrinks while AVGO invests at 19.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
5.47%
SG&A declining or stable vs. AVGO's 14.12%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.